Navigation Links
Nektar Therapeutics Reports First Quarter 2011 Financial Results
Date:4/27/2011

SAN FRANCISCO, April 27, 2011 /PRNewswire/ --  Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the quarter ended March 31, 2011.

Cash, cash equivalents, and short-term investments at March 31, 2011 were $518.6 million as compared to $315.9 million at December 31, 2010.

Revenue for the first quarter of 2011 decreased to $11.3 million as compared to $33.2 million in the first quarter of 2010.  This decrease in revenue year over year is primarily attributable to the completion as of December 31, 2010 of the amortization of the $125.0 million upfront payment received in 2009 from AstraZeneca for the NKTR-118 license agreement.  

Total operating costs and expenses in the first quarter of 2011 increased by 23% to $45.2 million, compared to $36.6 million in the first quarter 2010.  This increase was primarily a result of higher development expenses related to the advancement of multiple programs in clinical development.  Research and development expense increased to $30.2 million in the first quarter 2011 as compared to $23.3 million for the same quarter in 2010.  General and administrative expense increased to $11.7 million in the first quarter 2011 from $9.0 million in the first quarter of 2010.

“Nektar made great progress in the first quarter of 2011,” said Howard W. Robin, President and Chief Executive Officer of Nektar. “The first patients were enrolled in the comprehensive Phase 3 program for NKTR-118, and our proprietary next-generation opioid candidate, NKTR-181, entered Phase 1 clinical development.  We are also preparing our lead oncology candidate, NKTR-102, for advancement into Phase 3 development.  We continue to be highly focused on advancing our preclinical pipeline to enable the introduction of one new IND candidate each year.”

Net loss for the fi
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dennis Winger Joins Nektar Therapeutics Board of Directors
2. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
3. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
5. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
9. Nektar Therapeutics Reports First Quarter 2009 Financial Results
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
11. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... MD (PRWEB) July 28, 2014 ... personalized medicine, will be exhibiting data and research conducted ... International Spine Intervention Society’s (ISIS) 22nd Annual ... 3rd, at the Hyatt Regency, in Orlando, Florida. ... knowledge and clinical competence of physicians who care for ...
(Date:7/28/2014)... DALLAS , July 28, 2014 /PRNewswire/ ... research report  "Microbial Identification Market by Products (Consumables, Instruments, ... & Beverages), End User (Detection, Characterization) - ... global Microbial Identification Market is estimated at ... to reach $1,194.1 Million by 2019, growing ...
(Date:7/28/2014)... --  Propeller Health , the FDA-cleared digital health solution ... Brad Towle as Senior Vice President, Business and ... company,s sales growth, customer acquisition and program expansion. ... past role in the development of accountable care organizations, ... time in the industry," said David Van Sickle ...
(Date:7/28/2014)... 28, 2014 The global market for ... 2020, according to a new study by Grand View ... demand for effective vaccines and drugs in an attempt ... needs is expected to drive market demand over the ... agricultural productivity via the use of genetically engineered seeds ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4
... day that a research scientist and university professor gets to see ... few months, Richard W. Siegel will get to watch his name ... a new title that seems light years away from laboratory benches ... MAX," has been a three-year labor of love for Siegel. From ...
... IN KEY GLOBAL MARKETS, RANCHO CORDOVA, Calif., ... a leading supplier of innovative products and,services that ... it has signed,a distribution agreement with Celling Technologies ... stem cells from bone,marrow. The distribution rights are ...
... Sept. 9 For the second consecutive,year, MedNet ... study management systems, has been recognized by,Inc. magazine ... private,organizations. With consistently strong growth over the past ... in the Twin Cities,metro area, and fifth among ...
Cached Biology Technology:Professor-turned-producer learns the movie biz 2Professor-turned-producer learns the movie biz 3Professor-turned-producer learns the movie biz 4Professor-turned-producer learns the movie biz 5ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device 2ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device 3ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device 4MedNet Solutions Again Recognized as one of the Fastest Growing US Companies 2
(Date:7/28/2014)... map social connections in prairie dogs have uncovered ... on prairie dog communities that may help limit ... conservation efforts. The work was done by researchers ... Evolutionary Synthesis Center (NESCent). , "Prairie dogs are ... says Dr. Jennifer Verdolin, lead author of a ...
(Date:7/27/2014)... of mayfly in the southern Western Ghats, a mountain range ... the first time that any mayfly belonging to the genus ... The new species, called Labiobaetis soldani , "is named ... to the understanding of the Ephemeroptera of Palaearctic and Oriental ... the new mayfly in the Journal of Insect Science ...
(Date:7/27/2014)... over 18,000 patients, scientists have identified more than ... disease, including six that had not been previously ... , was partially funded by the National Institutes ... in NIH laboratories. , "Unraveling the genetic underpinnings ... mechanisms involved in this complex disease, and hopefully, ...
Breaking Biology News(10 mins):Social network research may boost prairie dog conservation efforts 2NIH scientists find 6 new genetic risk factors for Parkinson's 2
... brought honey bees (Apis mellifera) to the Americas, Mayan bee ... native to tropical forests. Now, colleagues from the Colegio de ... Tropical Research Institute (STRI) warn of the imminent demise of ... cultural change and habitat loss. , "In our initial surveys ...
... shark skin could help ships sailing smoothly. The growth ... is a major cause of increased energy costs in ... that prevents this so called 'bio-fouling'. , Ralph Liedert ... presenting his work on the application of artificial shark ...
... One teenager likes to snowboard off a cliff. Another ... trading places. Why these differences exist is a mystery, ... possible genetic explanation behind risk-seeking behavior. , Scientists ... a specific neurodevelopmental gene, called neuroD2, is related to ...
Cached Biology News:Mayan stingless bee keeping: Going, going, gone? 2Study identifies gene in mice that may control risk-taking behavior in humans 2Study identifies gene in mice that may control risk-taking behavior in humans 3
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
Mycoplasma tested...
Biology Products: